



LAWRENCE, EVANS & CO., LLC

Investment Banking | Healthcare Finance | Consulting

Healthcare Weekly News and Deals – January 5th, 2026

1. Happy New Year- Healthcare Investment and News Outlook for 2026
 - a. Pitchbook - 2026 Healthcare Outlook ([Link](#))
 - b. Forbes- The Healthcare Industry Outlook For 2026 ([Link](#))
 - c. Deloitte- 2026 US Health Care Outlook ([Link](#))
 - d. E&Y - Healthcare Sector Outlook: growing amid headwinds in 2026 ([Link](#))
 - e. PwC - US Deals 2026 outlook Health services ([Link](#))
2. FONAR Corporation (NASD: FONR) CEO Timothy Damadian Leads \$19 Per Share Take-Private Acquisition with OceanFirst Bank Financing

The buyer group, including management members, board directors, and third-party investors, will acquire all outstanding shares not already owned by the group at prices representing a 31.5% premium to pre-announcement closing and 39.7% premium to the 90-day average. A special committee of disinterested directors unanimously recommended the deal after independent review. Financing includes \$35 million from committed debt, \$10 million in subordinated debt, and \$45 million in equity contributions, with no financing contingencies. The transaction requires majority approval from all voting shares and disinterested shareholders, expected to close in fiscal Q3 2026, after which shares will be delisted from Nasdaq. ([Link](#))

3. Insilico Medicine partners with Servier in \$888M AI-Driven Cancer R&D Deal Following Hong Kong IPO

The collaboration will leverage Insilico's Pharma.AI platform to discover and develop drugs targeting challenging cancer targets, with Insilico receiving \$32 million in upfront and R&D payments. Insilico leads AI-driven discovery while Servier shares R&D costs and handles clinical validation and commercialization. The agreement follows Insilico's recent Hong Kong listing that raised \$293 million and builds on its 2025 momentum, including a \$110 million venture round and partnerships with pharmaceutical companies like Eli Lilly. For Servier, this represents another strategic move in its ambition to become a leading innovative pharma by 2030, following recent deals worth \$450 million with Kaerus Bioscience and \$210 million with Ideaya Biosciences. ([Link](#))

4. PathoCare Holdings Receives \$1.75B Valuation in Third-Party Tender Offer, Expands Financing Round with Lehrer Financial Assessment

The secondary share purchase follows the company's previous \$150 million venture investment, recapitalization, acquisition, and \$500 million secondary tender offer independently valued by Houston-based Lehrer Financial. PathoCare has appointed an independent financial advisory firm to conduct a formal fairness opinion and valuation review using recognized techniques, peer comparisons, and market data. The company simultaneously expanded its private equity financing

Healthcare Weekly News and Deals – January 2nd, 2026

round from \$25 million to \$50 million due to heightened institutional interest. Proceeds will fund product development, intellectual property expansion, regulatory readiness, engineering, and commercialization of its flagship PathoWand point-of-care diagnostic platform. ([Link](#))

5. Maimonides Health Joins NYC Health + Hospitals Under Mayor Eric Adams Deal to Stabilize Brooklyn Healthcare

The financially struggling Maimonides Health, a century-old community fixture in Brooklyn, will become part of the city's public health system pending regulatory approval expected before April 1. The partnership will enable Maimonides—which operates three hospitals and 80+ sites serving 600,000 outpatients and 35,000 inpatients annually—to receive higher Medicaid reimbursement rates and access NYC Health + Hospitals' electronic health records platform. Over 80% of Maimonides' admitted patients rely on Medicare or Medicaid, which reimburse only 60 cents per dollar compared to commercial insurance, contributing to annual losses of tens of millions, including \$165 million in 2021. ([Link](#))

6. Marlborough Hospital Becomes UMass Memorial Medical Center Campus Following Massachusetts Public Health Council Approval

The 79-bed facility, previously affiliated with UMass Memorial Health under an independent medical license, officially merged on January 1 after approval in July. The integration brings enhanced services including an expanded emergency department, new CT scanner, outpatient clinic, and improved cancer treatment capabilities. Despite the organizational change, patients will continue seeing the same medical staff while gaining broader access to specialty care, advanced technologies, and tertiary services through the coordinated clinical team, keeping more healthcare services available locally within the system's smallest campus. ([Link](#))

7. Proactive MD acquires California Ophthalmology Practices, Expands Value-Based Care Network

The Los Angeles-based healthcare leader adds multiple ophthalmology practices following recent expansions in Indiana, Texas, and Colorado. This acquisition strengthens Proactive MD's integrated healthcare solutions aimed at improving patient outcomes and reducing costs for employer-sponsored healthcare, health plan providers, and third-party administrators. Since launching its growth strategy in 2021, the company has expanded offerings to include clinical diagnostics, pathology services, occupational health, virtual and urgent care, healthcare technology, pharmacy products, and a 340B pharmacy provider network. The organization operates as the only national primary care provider owning and operating its own labs, pathology groups, pharmacies, 340B networks, and healthcare technology platforms. ([Link](#))

Venture and Other News

1. **Biobeat Technologies closes \$50 million Series B led by Ally Bridge Group, OrbiMed Advisors and Elevage Medical to expand U.S. commercialization of FDA-cleared cuff-less ambulatory blood pressure monitoring system**

The capital will fund a field sales team and commercial expansion for Biobeat's disposable patch device, which monitors blood pressure continuously for 24 hours without disruptive inflation cycles, allowing patients to maintain daily activities and sleep undisturbed. At test completion, the device is discarded and a high-quality report appears automatically in electronic medical records within seconds. The company welcomed Steven Plachtyna of Ally Bridge, Dina Chaya of OrbiMed and Evan Melrose of Elevage to its Board of Directors, underscoring its ambition to establish ABPM as a standard of care for diagnosing and titrating anti-hypertensive medications for the more than 100 million hypertensive patients in the United States. ([Link](#))

2. **Nacuity Pharmaceuticals raises \$12.89 Million Led by Foundation Fighting Blindness' Retinal Degeneration Fund and National Neurovision Research Institute**

The Fort Worth-based clinical-stage biotech developing antioxidant therapies for blinding eye diseases caused by oxidative stress secured \$12.89 million in funding led by Foundation Fighting Blindness' Retinal Degeneration Fund and National Neurovision Research Institute, with participation from undisclosed investors. This round brings the company's total funding to \$40.59 million. The capital supports Nacuity's advancement of its antioxidant therapeutic pipeline targeting retinal degenerative conditions. The involvement of specialized ophthalmology-focused investors underscores confidence in the company's approach to treating oxidative stress-related vision loss and its potential to address unmet needs in blinding eye disease treatment. ([Link](#))

3. **Alume Biosciences raises \$5.32 Million in Series C Venture Funding**

Alume Biosciences secured \$5.32 million in Series C venture funding as of December 31, 2025. This capital injection supports the company's ongoing development and expansion efforts. The funding round demonstrates continued investor confidence in the bioscience company's business model and technological platform. The specific use of proceeds and details regarding lead investors were not disclosed in the announcement. This represents a significant milestone in the company's growth trajectory as it advances its research, development, and commercialization initiatives within the biosciences sector. ([Link](#))